Updates on the development of vaccines and therapeutic options against rabies

Roshan Arjun Ananda, Hooi Leng Ser, Vengadesh Letchumanan

Research output: Contribution to journalReview ArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Even though rabies has been claiming more than 50,000 deaths annually worldwide, it is considered as a vaccinepreventable viral disease. More than 95 % of the total human rabies cases are caused by dogs. During the initial stage of infection, affected individuals usually show weakess at the bitten extremities and the virus can ultimately travel to the brain causing neurological signs. In attenuated (inactivated) form, the currently in use vaccines have been recommended by WHO for the prevention (i.e. pre-exposure prophylaxis, PrEP) and treatment (i.e. post exposure prophylaxis, PEP) regime against the rabies virus (RABV). However, given that they normally require refrigeration and are costly, there have been discussions revolving around potential development of newer, safer and cheaper alternative that can perform better and more convenient than the ones that are currently in use. The current review aims to explore general characteristics of RABV before looking into potential candidates of vaccines that have been studied. Further studies on the pathogenic mechanism of RABV and therapeutic approaches are still required to prevent the deathly infection following clinical manifestation. In sum, integrated interventional strategy emphasizing human health and animal health is essential and requires collaboration between health authorities and the public.

Original languageEnglish
Article numbera0000100
Number of pages8
JournalProgress in Microbes and Molecular Biology
Volume3
Issue number1
DOIs
Publication statusPublished - 26 Aug 2020

Keywords

  • development
  • rabies
  • therapeutic
  • treatment
  • vaccines

Cite this